Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Survey assessing prospective patient’s short-term treatment satisfaction and Quality of Life in patients with Hidradenitis Suppurativa initiated on Cosentyx (Secukinumab) in routine clinical practice in Saudi Arabia	Novartis	Ongoing	Secukinumab	4	CAIN457MSA	King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah)
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis	Argenx BV	Ongoing	Efgartigimod IV	3	ARGX-113-2308	King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh)
Effect and safety of Semaglutide in diabetic kidney transplant recipients with obesity	AbbVie	Ongoing	Risankizumab	3	M23-784	Aseer Central Hospital (Abha), International Medical Center (Jeddah), King Khalid University Hospital (Riyadh)
A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease	Global Therapeutics Inc	Ongoing	Osivelotor	2/3	C5351004 (GBT021601)	Prince Mohammad Bin Naser Hospital (Jazan), King Abdulaziz Medical City NG (Riyadh)
Effect and safety of Semaglutide in diabetic kidney transplant recipients with obesity	Astrazeneca	Ongoing	Anifrolumab	3	2241130	Aseer Central Hospital (Abha), International Medical Center (Jeddah), King Khalid University Hospital (Riyadh)
Comparing the effectiveness of buccal infiltration of different volumes of Articaine for extraction of mandibular posterior teeth- A randomized clinical trial.	Dental Clinic-collage of Dentistry-Qassim Unviersity	Ongoing	ARTICAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE	4	6074514624	Dental Clinic-collage of Dentistry-Qassim Unviersity (Al-Qassim)
The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency	Inozyme Pharma, Inc	Ongoing	INZ-701	3	INZ701-105	King Faisal Specialist Hospital and Research Center (Riyadh)
INTERnational STudy Evaluating Lupus Outcomes after Anifrolumab Real-World Use (INTERSTELLAR): Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice	Astrazeneca	Ongoing	Anifrolumab	4	TMP-0010230	Aseer Central Hospital (Abha), International Medical Center (Jeddah),King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment	Sanofi	Ongoing	amlitelimab	3	EFC17599	King Faisal Specialist Hospital and Research Center (Riyadh)
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease	Astrazeneca	Ongoing	Camizestrant (AZD9833)	3	8535C00001	King Faisal Specialist Hospital and Research Center (Riyadh)